These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

92 related articles for article (PubMed ID: 33530913)

  • 21. Neutralizing and binding activities against SARS-CoV-1/2, MERS-CoV, and human coronaviruses 229E and OC43 by normal human intravenous immunoglobulin derived from healthy donors in Japan.
    Kubota-Koketsu R; Terada Y; Yunoki M; Sasaki T; Nakayama EE; Kamitani W; Shioda T
    Transfusion; 2021 Feb; 61(2):356-360. PubMed ID: 33104267
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Coronaviruses - a new old menace.
    Golke A; Piekarska K; Dzieciątkowski T
    Postepy Biochem; 2020 Dec; 66(4):303-308. PubMed ID: 33470077
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The 2020 Pandemic: Current SARS-CoV-2 Vaccine Development.
    Alturki SO; Alturki SO; Connors J; Cusimano G; Kutzler MA; Izmirly AM; Haddad EK
    Front Immunol; 2020; 11():1880. PubMed ID: 32973779
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Biology and Pathogenesis of SARS-CoV-2: Understandings for Therapeutic Developments against COVID-19.
    Sharma HN; Latimore COD; Matthews QL
    Pathogens; 2021 Sep; 10(9):. PubMed ID: 34578250
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The Prediction of miRNAs in SARS-CoV-2 Genomes: hsa-miR Databases Identify 7 Key miRs Linked to Host Responses and Virus Pathogenicity-Related KEGG Pathways Significant for Comorbidities.
    Arisan ED; Dart A; Grant GH; Arisan S; Cuhadaroglu S; Lange S; Uysal-Onganer P
    Viruses; 2020 Jun; 12(6):. PubMed ID: 32512929
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [Etiology of epidemic outbreaks COVID-19 on Wuhan, Hubei province, Chinese People Republic associated with 2019-nCoV (Nidovirales, Coronaviridae, Coronavirinae, Betacoronavirus, Subgenus Sarbecovirus): lessons of SARS-CoV outbreak.].
    Lvov DK; Alkhovsky SV; Kolobukhina LV; Burtseva EI
    Vopr Virusol; 2020; 65(1):6-15. PubMed ID: 32496715
    [TBL] [Abstract][Full Text] [Related]  

  • 27. SARS-CoV-2 in environmental perspective: Occurrence, persistence, surveillance, inactivation and challenges.
    Mohan SV; Hemalatha M; Kopperi H; Ranjith I; Kumar AK
    Chem Eng J; 2021 Feb; 405():126893. PubMed ID: 32901196
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Recent Patents and Advances on Nanotechnologies against Coronavirus.
    Abedini-Nassab R; Mahdaviyan N
    Recent Pat Nanotechnol; 2021; 15(4):322-330. PubMed ID: 33172382
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Understanding the Molecular Biology of SARS-CoV-2 and the COVID-19 Pandemic: A Review.
    Alsobaie S
    Infect Drug Resist; 2021; 14():2259-2268. PubMed ID: 34163190
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Management of epigenomic networks entailed in coronavirus infections and COVID-19.
    El Baba R; Herbein G
    Clin Epigenetics; 2020 Aug; 12(1):118. PubMed ID: 32758273
    [TBL] [Abstract][Full Text] [Related]  

  • 31. A Genome Epidemiological Study of SARS-CoV-2 Introduction into Japan.
    Sekizuka T; Itokawa K; Hashino M; Kawano-Sugaya T; Tanaka R; Yatsu K; Ohnishi A; Goto K; Tsukagoshi H; Ehara H; Sadamasu K; Taira M; Shibata S; Nomoto R; Hiroi S; Toho M; Shimada T; Matsui T; Sunagawa T; Kamiya H; Yahata Y; Yamagishi T; Suzuki M; Wakita T; Kuroda M
    mSphere; 2020 Nov; 5(6):. PubMed ID: 33177213
    [TBL] [Abstract][Full Text] [Related]  

  • 32. SARS-CoV-2
    Lehrer S; Rheinstein PH
    In Vivo; 2020 Jun; 34(3 Suppl):1629-1632. PubMed ID: 32503821
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Vaccine Candidates against Coronavirus Infections. Where Does COVID-19 Stand?
    Al-Kassmy J; Pedersen J; Kobinger G
    Viruses; 2020 Aug; 12(8):. PubMed ID: 32784685
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Bioactive natural compounds against human coronaviruses: a review and perspective.
    Xian Y; Zhang J; Bian Z; Zhou H; Zhang Z; Lin Z; Xu H
    Acta Pharm Sin B; 2020 Jul; 10(7):1163-1174. PubMed ID: 32834947
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Evaluation on the use of Nanopore sequencing for direct characterization of coronaviruses from respiratory specimens, and a study on emerging missense mutations in partial RdRP gene of SARS-CoV-2.
    Chan WS; Au CH; Lam HY; Wang CLN; Ho DN; Lam YM; Chu DKW; Poon LLM; Chan TL; Zee JS; Ma ESK; Tang BSF
    Virol J; 2020 Nov; 17(1):183. PubMed ID: 33225958
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Characterization of codon usage pattern in SARS-CoV-2.
    Hou W
    Virol J; 2020 Sep; 17(1):138. PubMed ID: 32928234
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Mapping SARS-CoV-2 Antibody Epitopes in COVID-19 Patients with a Multi-Coronavirus Protein Microarray.
    Camerini D; Randall AZ; Trappl-Kimmons K; Oberai A; Hung C; Edgar J; Shandling A; Huynh V; Teng AA; Hermanson G; Pablo JV; Stumpf MM; Lester SN; Harcourt J; Tamin A; Rasheed M; Thornburg NJ; Satheshkumar PS; Liang X; Kennedy RB; Yee A; Townsend M; Campo JJ
    Microbiol Spectr; 2021 Oct; 9(2):e0141621. PubMed ID: 34704808
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The Enzymatic Activity of the nsp14 Exoribonuclease Is Critical for Replication of MERS-CoV and SARS-CoV-2.
    Ogando NS; Zevenhoven-Dobbe JC; van der Meer Y; Bredenbeek PJ; Posthuma CC; Snijder EJ
    J Virol; 2020 Nov; 94(23):. PubMed ID: 32938769
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Nanobiosensors for the Detection of Novel Coronavirus 2019-nCoV and Other Pandemic/Epidemic Respiratory Viruses: A Review.
    Alhalaili B; Popescu IN; Kamoun O; Alzubi F; Alawadhia S; Vidu R
    Sensors (Basel); 2020 Nov; 20(22):. PubMed ID: 33218097
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The «moonlighting protein» able to explain the T
    Roncati L; Lusenti B
    Med Hypotheses; 2020 Oct; 143():110087. PubMed ID: 32679426
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.